BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024
Expects Continued Revenue Growth in 2024 and Takes Steps to Further Improve Operating Efficiency as the Company Pursues Profitability Goals
LAKE FOREST, Calif., Jan. 29, 2024 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced preliminary unaudited revenue results for 2023 based on currently available information and expects to report year-over-year growth as it continues to generate interest among dental practitioners for its industry leading lasers. The Company is also taking additional steps to optimize operations and believes its revenue-generating strategies and prudent management of its expenses will enable it to achieve its sales and profitability goals in 2024.
Related news for (BIOL)
- BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
- BIOLASE Announces Delisting from Nasdaq
- Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability
- BIOLASE to Report First Quarter 2024 Results on May 13, 2024